<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00462553</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00212</org_study_id>
    <secondary_id>NCI-2009-00212</secondary_id>
    <secondary_id>CDR0000539459</secondary_id>
    <secondary_id>CASE 3206</secondary_id>
    <secondary_id>CASE 3206</secondary_id>
    <secondary_id>7731</secondary_id>
    <secondary_id>U01CA062502</secondary_id>
    <nct_id>NCT00462553</nct_id>
  </id_info>
  <brief_title>Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors</brief_title>
  <official_title>A Phase I Study of Sunitinib Malate and Standard Infusion Gemcitabine in Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of sunitinib and gemcitabine in&#xD;
      treating patients with pancreatic cancer or other solid tumors. Sunitinib may stop the growth&#xD;
      of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood&#xD;
      flow to the tumor. Drugs used in hemotherapy, such as gemcitabine, work in different ways to&#xD;
      stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving sunitinib together with gemcitabine may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose (MTD) of sunitinib malate and gemcitabine&#xD;
      hydrochloride in patients with adenocarcinoma of the pancreas or other solid tumors.&#xD;
&#xD;
      II. Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 OR on days 1,&#xD;
      8, and 15. Patients also receive oral sunitinib malate once daily on days 1-21 OR days 1-28.&#xD;
      Treatment repeats every 21 days OR every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of gemcitabine hydrochloride and sunitinib&#xD;
      malate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 10&#xD;
      patients may be treated at the recommended phase II dose (RPTD), which is generally the dose&#xD;
      level below the maximally administered dose.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 30 days and then periodically&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate assessed by Response Evaluation Criteria for Solid Tumors (RECIST)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Adenocarcinoma of the Pancreas</condition>
  <condition>Recurrent Pancreatic Cancer</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <condition>Stage IV Pancreatic Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 OR on days 1, 8, and 15. Patients also receive oral sunitinib malate once daily on days 1-21 OR days 1-28. Treatment repeats every 21 days OR every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>SU11248</other_name>
    <other_name>sunitinib</other_name>
    <other_name>Sutent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed pancreatic adenocarcinoma OR other solid&#xD;
             tumor:&#xD;
&#xD;
               -  Not amenable to curative therapy&#xD;
&#xD;
               -  Previously untreated metastatic pancreatic adenocarcinoma allowed&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No history of or known brain metastases, spinal cord compression, carcinomatous&#xD;
             meningitis, or new evidence of brain or leptomeningeal disease on screening CT scan or&#xD;
             MRI scan&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%&#xD;
&#xD;
          -  Life expectancy &gt;= 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mm3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin &gt;= 8.5 g/dL&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance &gt;= 60 mL/min&#xD;
&#xD;
          -  AST and ALT =&lt; 2.5 times upper limit of normal (ULN) (=&lt; 5 times ULN if due to&#xD;
             underlying disease)&#xD;
&#xD;
          -  Calcium =&lt; 12.0 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 6 months&#xD;
             after completion of study therapy&#xD;
&#xD;
          -  LVEF normal by MUGA scan or ECHO at baseline&#xD;
&#xD;
          -  Deep venous thrombosis or pulmonary embolism allowed provided they are clinically&#xD;
             stable and adequately treated&#xD;
&#xD;
          -  No preexisting thyroid abnormality that results in the inability to maintain thyroid&#xD;
             function in the normal range while using medication&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to sunitinib malate&#xD;
&#xD;
          -  No history of any of the following within the past 6 months:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation&#xD;
                  &gt;= 3 beats in a row)&#xD;
&#xD;
               -  Severe/unstable angina&#xD;
&#xD;
               -  Severe peripheral vascular disease (i.e., claudication)&#xD;
&#xD;
               -  Procedure on peripheral vasculature&#xD;
&#xD;
               -  Coronary/peripheral artery bypass graft&#xD;
&#xD;
               -  Cerebrovascular accident&#xD;
&#xD;
          -  No history of any of the following within the past 6 months:&#xD;
&#xD;
               -  Transient ischemic attack;&#xD;
&#xD;
               -  Clinically significant bleeding requiring red blood cell transfusion&#xD;
&#xD;
          -  No NYHA class III or IV heart disease:&#xD;
&#xD;
               -  Patients with NYHA class II disease who are stable and on medication are eligible&#xD;
&#xD;
          -  No ongoing cardiac dysrhythmias &gt;= grade 2, atrial fibrillation of any grade, or any&#xD;
             significant EKG abnormalities&#xD;
&#xD;
          -  No hypertension that cannot be controlled by medications to a systolic blood pressure&#xD;
             (BP) of &lt; 140 mm Hg and diastolic BP of &lt; 90 mm Hg&#xD;
&#xD;
          -  No condition that impairs the ability to swallow and retain sunitinib malate tablets,&#xD;
             including any of the following:&#xD;
&#xD;
               -  Gastrointestinal tract disease resulting in an inability to take oral medication&#xD;
&#xD;
               -  Requirement for IV alimentation&#xD;
&#xD;
               -  Prior surgical procedures affecting absorption&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
          -  No gastrointestinal perforation or intra-abdominal abscess within the past 28 days&#xD;
&#xD;
          -  No serious nonhealing infection or bone fracture&#xD;
&#xD;
          -  No other severe acute or chronic medical condition, psychiatric condition, or&#xD;
             laboratory abnormality that would preclude study therapy&#xD;
&#xD;
          -  May have received any number of prior systemic therapies&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy or surgery and recovered&#xD;
&#xD;
          -  More than 4 weeks since other prior therapies and recovered&#xD;
&#xD;
          -  Prior gemcitabine hydrochloride allowed&#xD;
&#xD;
          -  No prior sunitinib malate or other therapy directed against VEGF, including any of the&#xD;
             following:&#xD;
&#xD;
        Sorafenib; Bevacizumab; Vatalanib; AZD2171; VEGF Trap; Investigational antiangiogenic&#xD;
        therapy&#xD;
&#xD;
          -  More than 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Indinavir&#xD;
&#xD;
               -  Ritonavir&#xD;
&#xD;
               -  Nelfinavir&#xD;
&#xD;
               -  Saquinavir&#xD;
&#xD;
               -  Atazanavir&#xD;
&#xD;
               -  Delavirdine&#xD;
&#xD;
          -  More than 12 days since prior and no concurrent CYP3A4 inducers, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Rifabutin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Efavirenz&#xD;
&#xD;
               -  Tipranavir&#xD;
&#xD;
          -  No concurrent agents with proarrhythmic potential, including any of the following:&#xD;
&#xD;
               -  Terfenadine&#xD;
&#xD;
               -  Quinidine&#xD;
&#xD;
               -  Procainamide&#xD;
&#xD;
               -  Disopyramide&#xD;
&#xD;
               -  Sotalol&#xD;
&#xD;
               -  Probucol&#xD;
&#xD;
               -  Bepridil&#xD;
&#xD;
               -  Haloperidol&#xD;
&#xD;
               -  Risperidone&#xD;
&#xD;
               -  Indapamide&#xD;
&#xD;
               -  Flecainide&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent treatment on another clinical trial:&#xD;
&#xD;
        Participation in non-therapeutic clinical trials allowed&#xD;
&#xD;
          -  QTc &lt; 500 msec&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Smitha Krishnamurthi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2007</study_first_posted>
  <last_update_submitted>February 21, 2014</last_update_submitted>
  <last_update_submitted_qc>February 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

